Custom Compounded Therapy Market Report 2025

The custom compounded therapy market size has grown strongly in recent years. It will grow from $5.52 billion in 2024 to $5.96 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth during the historic period is attributed to the rising demand for personalized medicine, increasing prevalence of chronic diseases, growth in pediatric and geriatric populations, greater incidence of drug shortages, and a rise in patient-specific allergies and intolerances.

The custom compounded therapy market size is expected to see strong growth in the next few years. It will grow to $7.97 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth during the forecast period is driven by the wider adoption of 3D printing technologies, expanding healthcare infrastructure in emerging markets, the growing aging population, and rising awareness of personalized treatments. Key trends in the forecast period include advancements in automated compounding systems, development of patient-specific dosage forms, innovation in hormone replacement therapies, progress in pediatric compounding solutions, and the creation of compounded veterinary medications.

The increasing interest in personalized medications is contributing to the expansion of the custom compounded therapy market. Personalized medication involves adapting medical treatments to fit the unique characteristics, conditions, and preferences of each individual, often based on factors such as genetics, clinical history, and lifestyle. This approach is gaining popularity due to its potential to enhance treatment effectiveness and minimize adverse drug reactions by aligning therapies more closely with a patient's specific profile. Custom compounded therapy supports this approach by formulating medications in precise doses, unique combinations, and alternative delivery forms to meet each patient's requirements, leading to better therapeutic results. For example, in February 2024, the Personalized Medicine Coalition, a nonprofit organization based in the United States, reported that the U.S. Food and Drug Administration approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. This rising demand for customized care is driving growth in the custom compounded therapy market.

Companies active in this market are introducing advanced technologies such as automated compounding systems to improve the accuracy, consistency, and safety of preparing personalized medications. A pharmaceutical compounding device is a specialized tool that precisely mixes and measures ingredients to create medication tailored to the specific needs of individual patients. In December 2022, Baxter International Inc., a healthcare company based in the United States, introduced the ExactaMix Pro Automated Compounder. This system is designed to enhance the accuracy and safety of medication compounding processes. It builds on the original ExactaMix system, which is used in over one thousand pharmacies worldwide and has been involved in the preparation of more than one hundred million bags. The ExactaMix Pro is also the first automated compounder certified under the cybersecurity standard recognized by the U.S. Food and Drug Administration, known as UL 2900-2-1.

In April 2024, Myonex Inc., a clinical trial supply company based in the United States, acquired SaveWay Compounding Pharmacy Inc. for an undisclosed amount. Through this acquisition, Myonex seeks to enhance its clinical trial services across the country by incorporating SaveWay’s expertise in custom-compounded medications. This move strengthens Myonex’s ability to provide personalized drug formulations and ensures consistent access to specialized therapies for both patients and clinical research initiatives. SaveWay Compounding Pharmacy is a pharmacy in the United States that focuses on producing customized sterile and non-sterile medications tailored to individual patient needs.

Major players in the custom compounded therapy market are Hikma Pharmaceuticals PLC, Fagron N.V., Nephron Pharmaceuticals Corporation, Belmar Pharmacy LLC, Empower Clinic Services LLC, Medisca Pharmaceutique Inc., Central Admixture Pharmacy Services Inc. (CAPS), Wedgewood Connect LLC, AnazaoHealth Corporation, Wells Pharmacy Network LLC, Institutional Pharmacy Solutions Inc., KRS Global Biotechnology Inc., Bennett Pharmaceuticals of America LLC, Annovex Pharma Inc., Bravado Pharmaceuticals LLC, Pencol Compounding Pharmacy Inc., Rx3 Compounding Pharmacy Inc., CareFirst Specialty Pharmacy LLC, Vertisis Custom Pharmacy LLC, FarmaKeio Pharmacy Network LLC.

North America was the largest region in the custom compounded therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in custom compounded therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the custom compounded therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Custom compounded therapy refers to the preparation of personalized medications by pharmacists, designed to address the specific requirements of individual patients when standard treatments are not appropriate. The aim is to deliver tailored dosages, formulations, or ingredients to enhance treatment effectiveness, safety, and patient adherence.

The primary product types of custom compounded therapy include hormone replacement therapy, pain management, dermatology, nutritional supplements, and others. Hormone replacement therapy is a medical approach that restores or supplements hormones in the body to ease symptoms resulting from hormone deficiencies or imbalances. These therapies are offered in different forms, such as intravenous (IV) therapy, topical therapy, oral therapy, and subcutaneous therapy, with formulations including injectable, oral, and transdermal. They are applied in therapeutic areas such as oncology, neurology, cardiology, endocrinology, and pain management, and are utilized by key end-users including hospitals, clinics, homecare settings, and specialty pharmacies.

The custom compounded therapy market research report is one of a series of new reports that provides custom compounded therapy market statistics, including the custom compounded therapy industry global market size, regional shares, competitors with the custom compounded therapy market share, detailed custom compounded therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the custom compounded therapy industry. This custom compounded therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The custom compounded therapy market consists of revenues earned by entities by providing services such as compounding pharmacy services, personalized consultations, prescription customization, and ongoing patient care support. The market value includes the value of related goods sold by the service provider or included within the service offering. The custom compounded therapy market also includes sales of topical creams, gels, sterile injectables, transdermal patches, and veterinary compounded medications. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.